GlaxoSmithKline Pharmaceuticals Ltd. - Research Center
500660 GLAXO Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Sales | 3,216.34 | 3,217.51 | 3,193.73 | 3,224.68 | 3,128.53 |
| Operating profit | 799.41 | 755.83 | 694.95 | 658.45 | 606.48 |
| Interest | 1.81 | 1.99 | 3.53 | 6.34 | 0.55 |
| Gross profit | 899.12 | 830.06 | 801.61 | 729.67 | 707.41 |
| EPS (Rs) | 35.87 | 99.79 | 21.11 | 6.50 | 25.11 |
Annual
results in details
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Other income | 101.52 | 76.22 | 110.19 | 77.56 | 101.48 |
| Stock adjustment | 67.25 | 13.83 | -27.53 | -35.43 | 25.57 |
| Raw material | 394.35 | 552.47 | 452.64 | 474.38 | 682.07 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 594.99 | 610.23 | 614.69 | 628.55 | 537.20 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,360.34 | 1,285.15 | 1,458.98 | 1,498.73 | 1,277.21 |
| Provisions made | - | - | - | - | - |
| Depreciation | 65.77 | 68.19 | 79.28 | 82.68 | 48.59 |
| Taxation | 227.68 | 396.87 | 192.17 | 212.45 | 238.35 |
| Net profit / loss | 607.75 | 1,690.53 | 357.56 | 110.05 | 425.36 |
| Extra ordinary item | 2.08 | 1,325.53 | -172.60 | -324.49 | 4.89 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 169.41 | 169.41 | 169.41 | 169.41 | 169.41 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 24.85 | 23.49 | 21.76 | 20.42 | 19.39 |
| GPM (%) | 27.10 | 25.20 | 24.26 | 22.10 | 21.90 |
| NPM (%) | 18.32 | 51.33 | 10.82 | 3.33 | 13.17 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis